Sign In

Expanding the Boundaries for Liver Transplant Oncology

Date/Time

  • Friday, November 9, 8:00 am – 3:00 pm

Program Chairs

  • Roberto Hernandez-Alejandro, MD
  • Mitra K. Nadim, MD
  • Marina Berenguer, MD

Session Description / Needs Statement

Approximately 24,000 liver transplants are performed annually worldwide. Survival is excellent and continues to improve, with one-year survival currently exceeding 85%. Unfortunately, there remains a gap between the need for liver transplantation and the number of available donor organs. To close this gap, there is a need to innovative procurement and optimization of donor organs. This course will look at the impact of anti-HCV therapies, donation after cardiac death and perfusion strategies in donor organ availability. The course will also review the knowledge of liver transplant oncology (including out-of-Milan hepatocellular carcinoma) cholangiocarcinoma and colon cancer metastasis. Finally, the course will discuss ways attendees can ensure ongoing innovation and expanding the utility of transplantation.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Understand the impact of anti-HCV therapies, donation after cardiac death and perfusion strategies in donor organ availability
  • Update the knowledge of liver transplant oncology, including out-of-Milan hepatocellular carcinoma, cholangiocarcinoma and colon cancer metastasis
  • Promote self and program analysis to ensure ongoing innovation and expanding the utility of transplantation

Continuing Education Information

  • CME – 5.75 AMA PRA Category 1 Credits™
  • CE – 5.5 Hours
  • * (eligible for 4.25 pharmacology hours)

 

Session I: Increasing Donor Organ Availability

Moderator: TBD

  • 8:00 am - 8:10 am
    Welcome and Introductions
  • 8:10 am - 8:30 am
    The End of the HCV Epidemic: An Opportunity for Spare Organs
  • 8:30 am - 8:50 am
    DCD: The Solution to Expand Organ Availability (YES?)
    DCD: The Solution to Expand Organ Availability (NO?)
  • 8:50 am - 9:10 am
    Perfusion Strategies and Organ Repair: Where’s the Limit?
  • 9:10 am - 9:30 am
    Matching Donors and Recipients to Achieve the Best Outcomes
  • 9:30 am - 9:50 am
    Panel Discussion
  • 9:50 am - 10:10 am
    Break

Session II: State-of-the-Art in Transplant Oncology: What’s Working, What’s Not?

Moderator: TBD

  • 10:10 am - 10:25 am
    HCC for Outside Milan Criteria: Current Evidence
  • 10:25 am - 10:40 am
    Downstaging Strategies: Pre-LT Approaches
  • 10:40 am - 10:55 am
    LT vs Resection for the Very Small HCC
  • 10:55 am - 11:10 am
    Hilar Cholangiocarcinoma
  • 11:10 am - 11:25 am
    Neuroendocrine Tumors vs Liver Resection vs Non-surgical Options
  • 11:25 am - 11:40 am
    Pediatrics Transplant Oncology
  • 11:40 am - Noon
    Panel Discussion
  • Noon - 1:00 pm
    Intermission

Session III: Pushing the Envelope: Innovation in Medical Oncology

Moderator: TBD

  • 1:00 pm - 1:15 pm
    Colorectal Liver Metastases
  • 1:15 pm - 1:30 pm
    Intrahepatic Cholangiocarcinoma or HCC-CC
  • 1:30 pm - 1:50 pm
    LDLT vs Deceased Donors (Deceased Donors)
    LDLT vs Deceased Donors (Live Donors)
  • 1:50 pm - 2:10 pm
    Immunosuppression and Chemotherapy in Transplant Oncology (Immunosuppression)
    Immunosuppression and Chemotherapy in Transplant Oncology (Chemotherapy)
  • 2:10 pm - 2:30 pm
    The Contribution of Radiology and Pathology in Transplant Oncology (Radiology)
    The Contribution of Radiology and Pathology in Transplant Oncology (Pathology)
  • 2:30 pm - 2:50 pm
    Panel Discussion
  • 2:50 pm - 3:00 pm
    Closing Remarks